Positive Results of Phase II Study of AMEVIVE Presented

January 2000
Worldwide Biotech;Jan2000, Vol. 12 Issue 1, p7
Trade Publication
Reports on the results of the Phase II clinical study of the AMEVIVE Clinical Study Group at the `Psoriasis: Gene to Clinic Meeting' announced by Biogen, Inc.


Related Articles

  • Biogen Targets Amevive Launch. Krause, Carey // Chemical Market Reporter;9/23/2002, Vol. 262 Issue 10, p12 

    Reports on the focus of Biogen Inc.'s marketing efforts on the psoriasis market. U.S. Food and Drug Administration's commitment to a review of Biogen's biologic license application for Amevive which it categorized as a treatment for psoriasis; Analysts' assessment of the sales potential of...

  • Biogen Stumbles on European Agency Approval of Amevine. Krause, Carey // Chemical Market Reporter;3/3/2003, Vol. 263 Issue 9, p7 

    Reports on the decline in the Biogen Inc.'s stocks in February 2003. Factors contributing to the stock price decline; Analysts' lowering of its earnings per share estimates for 2003; Advisory panel of the European Medicines Evaluation Agency's request for additional information relating to the...

  • New data shows Amevive provides relief from psoriasis for a median of seven months.  // PharmaWatch: Biotechnology;August 2003, Vol. 2 Issue 8, p11 

    Focuses on the clinical research of Amevive, a drug for the treatment of psoriasis developed by Biogen Inc. Presentation of the clinical study of Amevive; Efficacy of the drug to treat psoriasis; Patients enrolled in the clinical research.

  • Two biotech companies lead attack on psoriasis. Gebhart, Fred // Drug Topics;7/16/2001, Vol. 145 Issue 14, p16 

    Provides information on the antipsoriasis drugs developed by Genentech and Biogen. Information on plaque psoriasis, a common form of the disease; Side effects of Genentech's efalizumab and Biogen's alefacept.

  • CLINICAL DERMATOLOGY: PSORIASIS BRIEFS.  // Dermatology Times;Sep2003, Vol. 24 Issue 9, p47 

    Reports developments related to dermatology in the U.S. as of September 2003. Approval of Food and Drug Administration of Biogen Inc.'s construction of a large-scale manufacturing plant; Results from the clinical studies of the efficacy of Raptiva in treating psoriasis; Development of...

  • Genentech/XOMA: forget arthritis, time to focus on psoriasis.  // PharmaWatch: Biotechnology;June 2003, Vol. 2 Issue 6, p12 

    Reports on the disappointing results of the clinical trial for Raptiva from Genentech Inc. in rheumatoid arthritis. Focus of the company on psoriasis; Competition faced by the drug from Amevive by Biogen Inc. and Enbrel by Amgen Inc.; Evaluation of the clinical benefits of Raptiva undertaken by...

  • Biogen patent revoked.  // Chemical Market Reporter;04/14/97, Vol. 251 Issue 15, p5 

    Reports that the Technical Board of Appeals of the European Patent Office (EPO) has revoked Biogen Inc.'s European patent for the production of recombinant beta interferon. Reasons for the revocation.

  • Training in self injection is essential.  // Inside MS;Fall96, Vol. 14 Issue 3, p6 

    Focuses on the importance of self-injection training for the application of Avonex. Video and handbook prepared by Biogen; Hands-on training session.

  • Biogen Moves Into Europe.  // Chemical Market Reporter;5/21/2001, Vol. 259 Issue 21, p3 

    Reports on the investment of Biogen Inc. to construct its first major European manufacturing facility in Hillerod, Denmark. What the facility will include; Comments from company's President James C. Mullen about the facility.

  • Biogen Reports Strong 2Q Results as It Battles with Serono over MS Drug. Krause, Carey // Chemical Market Reporter;7/23/2001, Vol. 260 Issue 4, p8 

    Reports on the growth of Biogen Inc. in the second quarter of 2001. Biogen's earnings per share in the second quarter of 2001; Sales the company is targeting in year 2001; Competition between Biogen and Serono to gain share of the market for relapse-remitting multiple sclerosis.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics